A new North American commercialization partner for biosimilar ranibizumab is being sought by Stada and Xbrane Biopharma after the pair announced that a previous deal with Bausch+Lomb had been “discontinued by mutual consent.”
With the ranibizumab candidate currently awaiting US Food and Drug Administration approval – after refiling the biosimilar earlier this year,...






